

BioLight Offers to Increase its Equity Stake in Micromedic

TEL AVIV (February 24, 2015) - BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT; OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its intention to increase its equity stake in Micromedic, its subsidiary that manages the cancer diagnostic portfolio, through a private placement of Micromedic's shares.

According to the terms disclosed, the private placement includes an offering of 5,253,486 Micromedic Ordinary Shares in consideration for NIS 0.27 per share (based on to the average closing price per share in the 10 trading days preceding the date of the offer), for a total consideration of approx. NIS 1,418,000.

Subject to the consummation of the private placement, BioLight is expected to hold approximately 46% of Micromedic's issued share capital (approximately 46.15% on a fully diluted basis).

The consummation of the private placement is subject to the fulfillment of the following conditions:

- Receipt of the approval of TASE for registering Micromedic's shares contemplated by the private placement for trade;
- Since BioLight already has controlling ownership over Micromedic prior to the private placement, an approval of the private placement by the Micromedic shareholders meeting.